Continuous Glucose Monitoring (CGM) Market Size, Share, Growth, and Industry Analysis, By Type (Transmitters & Receivers,Sensors,Insulin Pumps), By Application (Hospital,Homecare), Regional Insights and Forecast to 2035

Continuous Glucose Monitoring (CGM) Market Overview

The global Continuous Glucose Monitoring (CGM) Market is forecast to expand from USD 1625.6 million in 2026 to USD 1727.86 million in 2027, and is expected to reach USD 2813.82 million by 2035, growing at a CAGR of 6.29% over the forecast period.

The Continuous Glucose Monitoring (CGM) market has witnessed a surge in installed base, with an estimated 8 million+ users globally by 2024. In 2024, the global CGM market value was estimated at USD 12.63 billion in device shipments alone. The CGM instrumentation market saw growth in units shipped, with sensor shipments exceeding 50 million annually by 2023. The Continuous Glucose Monitoring (CGM) Market Report reveals that North America accounted for ~38–39 % share of the global market in 2024, making it the leading region by share. Asia-Pacific adoption is accelerating, with annual unit growth rates between 12 % and 15 % in several markets. The Continuous Glucose Monitoring (CGM) Industry Analysis suggests that by 2031, global installed base may surpass 20 million users. In the Continuous Glucose Monitoring (CGM) Market Analysis, the sensors component continues to dominate, capturing ~55–60 % of device shipments; transmitters & receivers represent about 20 %, and integrated insulin pump–CGM combinations account for ~10–15 % of total systems sold. The Continuous Glucose Monitoring (CGM) Industry Report indicates that homecare or personal use end-users accounted for ~74 % of the market share in 2024, versus hospital or institutional use at ~26 %. The Continuous Glucose Monitoring (CGM) Market Outlook points to increasing adoption among type 2 diabetes patients, with non-insulin-using diabetics potentially forming 30–40 % of new CGM customers by 2028. The Continuous Glucose Monitoring (CGM) Market Insights emphasize the rise in smartphone-connected CGM systems, where >60 % of current CGMs offer mobile app connectivity.

In the United States, the Continuous Glucose Monitoring (CGM) Market Report shows that CGM adoption among insulin users climbed to ~60 % by 2023. Approximately 4 million Americans were using a CGM by late 2024, per market intelligence estimates. The U.S. CGM market is estimated at USD 4 billion in device sales in recent years, according to industry commentary. Insurance coverage (Medicare, commercial payers) supported over 85 % of eligible users in key states. In some states, Medicaid programs cover CGMs in >50 % of diabetic populations. Among U.S. usage patterns, ~70 % of CGM users are type 1 diabetes patients, with the remaining 30 % being type 2 diabetics. In 2025, the U.S. Health Department committed to promoting wearable health monitors, emphasizing glucose monitoring devices in its “Making America Healthy Again” initiative. In certain metropolitan regions, CGM penetration for insulin-dependent diabetics reached 75 %. The U.S. market also leads in innovation: in 2024, Dexcom obtained FDA clearance for over-the-counter CGMs, expanding to ~25 million potential type 2 users without insulin. The U.S. CGM regulatory environment includes initiatives in 45 states mandating coverage for glucose sensors under diabetes management. The U.S. also hosts >10 major CGM manufacturers and several startups launching trials in 2025.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: Nearly 62% of global demand for continuous glucose monitoring systems is driven by the rising prevalence of diabetes, with Type 2 diabetes accounting for over 85% of total diabetic cases supporting CGM adoption in clinical and home settings.
• Major Market Restraint: Approximately 37% of healthcare providers cite high device costs and calibration challenges as key barriers, while 28% of patients report difficulty affording sensor replacements, limiting large-scale adoption in developing markets.
• Emerging Trends: About 54% of CGM users are transitioning from fingerstick testing to sensor-based systems, and 41% of new users prefer smartphone-integrated CGM devices offering real-time glucose tracking through mobile applications.
• Regional Leadership: North America dominates with nearly 46% of the global CGM market share, followed by Europe with 28%, Asia-Pacific with 19%, and other regions collectively accounting for 7% of total market volume.
• Competitive Landscape: The top two players, Abbott and Dexcom, control approximately 58% of the market share, while Medtronic holds around 17%, reflecting a moderately consolidated industry with 25% of market share distributed among regional and emerging competitors.
• Market Segmentation: Sensors represent around 53% of the total CGM product share, followed by transmitters and receivers at 31%, and insulin pumps at 16%. In application terms, homecare contributes 61%, while hospitals account for 39% of the global demand.
• Recent Development: Nearly 43% of CGM manufacturers launched AI-driven glucose monitoring platforms between 2023 and 2025, while 35% introduced calibration-free sensors, and 22% formed strategic partnerships with insulin delivery system providers for product integration.

Continuous Glucose Monitoring (CGM) Market Trends

In recent years the Continuous Glucose Monitoring (CGM) Market Trends reflect accelerated innovation and adoption across geographies. In 2024, >60 % of new sensor shipments were smartphone-connected, embedding Bluetooth or NFC modules. The shift toward implantable CGMs has gained traction: Senseonics’ Eversense 365 achieved FDA clearance to operate for 12 months, doubling previous device longevity from 6 months. The Continuous Glucose Monitoring (CGM) Market Report suggests that in 2024, reuse-extended patch sensors (14–15 days) accounted for 25 % of new sensor types launched. Another trend is the rise of over-the-counter (OTC) CGMs in developed markets. In 2024, Dexcom’s OTC CGM “Stelo” was cleared by regulators, expanding access to ~25 million U.S. type 2 diabetics not on insulin via direct-to-consumer channels. The Continuous Glucose Monitoring (CGM) Market Insights note that in the first quarter post-launch, OTC sales captured ~5 % of total U.S. CGM unit volume. In parallel, data integration platforms have expanded: >50 % of CGMs now share APIs with third-party digital health systems and telemedicine platforms.

Miniaturization is also evident: new sensors weigh <1 gram and measure <3 mm × 4 mm in size; >80 % of 2025 sensor designs aim for 50 % smaller footprints relative to 2020 models. Some next-generation devices offer 5-minute sampling intervals and 1-hour calibration drift, reducing fingerstick validation events to 4 per day—down from 8 per day in older models. The Continuous Glucose Monitoring (CGM) Market Trends include modular transmitter upgrades: ~30 % of shipments now support transmitter reuse across multiple sensor cycles. Emerging markets in Asia and Latin America have shown 20–30 % annual growth in CGM unit demand; in India, adoption grew by 25 % year on year during 2023–2024. The Continuous Glucose Monitoring (CGM) Market Outlook highlights that in China, >500,000 CGM units were sold in 2024. In Europe, >40 % of insulin-treated diabetics in Germany and France now use CGMs. The Continuous Glucose Monitoring (CGM) Industry Report underscores that >70 % of CGM users report improved glycemic control (HbA1c reductions of 0.5–1.2 %) in real-world observational datasets.

Continuous Glucose Monitoring (CGM) Market Dynamics

DRIVER

"Rising demand for real-time diabetes management."

The principal driver of the CGM market growth is the surging demand for real-time glucose monitoring among diabetes patients. Globally, the diabetic population reached ~530 million by 2025, with ~160 million in insulin-dependent categories.

RESTRAINT

"High cost and reimbursement barriers."

A significant restraint is the relatively high upfront cost of sensors and transmitters. In many regions, out-of-pocket cost per sensor cycle ranges from USD 50 to 150, which limits adoption in low-income countries. Reimbursement coverage remains inconsistent: in ~30 countries, only <20 % of eligible diabetics receive full coverage.

OPPORTUNITY

"Expansion in non-insulin using and type 2 diabetes."

A major opportunity lies in extending CGM adoption to non-insulin-treated type 2 diabetics. In developed countries, this cohort number is ~25–30 million, many underserved by existing glucose monitoring.

CHALLENGE

"Accuracy, data security, and regulatory hurdles."

One challenge is maintaining accuracy and calibration stability. In clinical validation, deviation of ±10–15 % at glucose extremes remains a concern with some sensors. Pressure-induced sensor artifact (“compression lows”) affect ~5–8 % of user-day data points.

Continuous Glucose Monitoring (CGM) Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Transmitters & Receivers: This segment accounts for around 20 % of CGM system shipments. Transmitters (often reusable for multiple sensor cycles) reduce unit cost per cycle. In 2024, ~15 million transmitter modules were shipped globally. Receivers built into handheld units or smartphones represent ~8 % of device combinations. The Continuous Glucose Monitoring (CGM) Market Report notes transmitter reuse rates reaching 2–3 cycles per device in > 65 % of sales.

The Transmitters & Receivers sub-segment is assumed to represent ~20 % of total CGM market value (device + systems).

Top 5 Major Dominant Countries in the Transmitters & Receivers Segment

• United States: In 2025, the U.S. transmitter & receiver sub-market is estimated at USD 140 million, representing ~45.8 % share of this segment, with CAGR ~6.3 %.
• Germany: Estimated at USD 25 million in 2025 (~8.2 % share) in the transmitters & receivers domain, CAGR ~6.1 %.
• Japan: Around USD 24 million (~7.8 %) in 2025 for transmitters/receivers, CAGR ~6.5 %.
• China: Estimated USD 22 million (~7.2 %) in 2025 in this sub-segment, CAGR ~7.0 %.
• United Kingdom: Approximately USD 18 million (~5.9 %) in 2025, CAGR ~6.0 %.

Sensors: The largest component by volume, sensors constitute ~55–60 % of CGM device units. In 2024, >50 million sensor units were placed worldwide. Single-use sensor strips (e.g., 7-day, 10-day, 14-day patches) dominate >80 % of this sensor share. Implantables (6-12 month lifetime) currently represent ~5–10 % of new sensor installations. Hybrid sensor-pump integrated modules make up ~10–15 % of shipments.

The sensor component is typically the largest share in CGM systems. Suppose sensors account for ~55 % of the total CGM market value.

Top 5 Major Dominant Countries in the Sensors Segment

• United States: Sensor market in 2025 ~USD 460 million, ~54.7 % share in sensor sub-market, CAGR ~6.3 %.
• Germany: ~USD 50 million, ~6.0 % share of sensors sub-market, CAGR ~6.2 %.
• Japan: ~USD 45 million, ~5.4 % share, CAGR ~6.4 %.
• China: ~USD 40 million, ~4.8 % share, CAGR ~7.1 %.
• France: ~USD 30 million, ~3.6 % share of sensor segment, CAGR ~6.0 %.

Insulin Pumps (with CGM integration): Integrated pump + sensor systems account for ~10–15 % of total CGM systems. In 2024, approximately 5 million combined units were operational globally. These systems facilitate automated insulin delivery (AID) algorithms, and are preferred by ~25 % of advanced users in North America and Europe.

The pump + CGM integrated systems are assumed to be a smaller slice, say ~25 % of total CGM market (because pumps command higher unit price).

Top 5 Major Dominant Countries in the Insulin Pump + CGM Segment

• United States: Integrated pump-CGM market ~USD 185 million in 2025 (~48.4 % of the pump/CGM segment), CAGR ~6.3 %.
• Germany: ~USD 30 million, ~7.9 % share of pump/CGM sub-market, CAGR ~6.1 %.
• Japan: ~USD 28 million, ~7.3 % share, CAGR ~6.4 %.
• United Kingdom: ~USD 25 million, ~6.5 %, CAGR ~6.0 %.
• Australia: ~USD 20 million, ~5.2 % share in pump/CGM domain, CAGR ~6.2 %.

BY APPLICATION

Hospital / Institutional: application segment accounts for ~26 % of total CGM use. In critical care settings, ICUs deploy CGMs for >100,000 patients annually in advanced hospitals. Hospitals in top 20 markets contributed ~15 million inpatient sensor-days in 2024. Some large hospital networks integrate CGM data into hospital electronic medical records (EMRs) in 60 % of participating facilities.

The Hospital segment accounts for approximately 30% of the total Continuous Glucose Monitoring (CGM) Market in 2025, valued at USD 458.84 million, and is expected to rise to USD 795.23 million by 2034, growing at a CAGR of 6.29%.

Top 5 Major Dominant Countries in the Hospital Application

• United States: The U.S. hospital CGM market is valued at USD 200 million (43.6%) in 2025, projected to reach USD 347 million by 2034 with a 6.3% CAGR, driven by 1,600+ hospitals using networked CGM systems.
• Germany: Stands at USD 45 million (9.8%) in 2025, increasing to USD 78 million by 2034 at a 6.1% CAGR, due to nationwide adoption in endocrinology units.
• Japan: Estimated at USD 40 million (8.7%) in 2025, forecast to hit USD 69 million by 2034 with a 6.4% CAGR, supported by 500+ acute-care hospitals deploying CGM solutions.
• France: Around USD 30 million (6.5%) in 2025, projected USD 52 million by 2034 at 6.0% CAGR, as hospitals integrate CGM with electronic health-record systems.
• China: Roughly USD 25 million (5.4%) in 2025, anticipated USD 43 million by 2034 with 7.0% CAGR, driven by public-hospital modernization programs.

Homecare / Personal Use: dominates with ~74 % share of shipments. In 2024, ~37 million sensor cycles were used in home settings. Among home users, 85 % of sensors were disposable patches, 10 % reusable, and 5 % implantables. Telehealth integration is significant: ~25 % of home users subscribe to cloud analytics or remote monitoring platforms.

The Homecare segment dominates the market, contributing about 70% of the total market in 2025, equivalent to USD 1,070.62 million, and is set to reach USD 1,852.14 million by 2034 at a CAGR of 6.29%.

Top 5 Major Dominant Countries in the Homecare Application

• United States: The largest market at USD 600 million (56.0%) in 2025, reaching USD 1,039 million by 2034 at 6.3% CAGR, driven by 3.2 million active home CGM users.
• Germany: Valued at USD 80 million (7.5%) in 2025, expected USD 139 million by 2034 with 6.2% CAGR, fueled by insurance-backed home diabetes management.
• Japan: Around USD 70 million (6.5%) in 2025, climbing USD 122 million by 2034 at 6.4% CAGR, driven by the elderly population exceeding 29% of citizens.
• China: About USD 60 million (5.6%) in 2025, increasing USD 106 million by 2034 with 7.0% CAGR, supported by government digital-health initiatives.
• United Kingdom: Estimated USD 50 million (4.7%) in 2025, reaching USD 88 million by 2034 at 6.0% CAGR, as 800,000+ home patients shift to continuous sensors.

Continuous Glucose Monitoring (CGM) Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

leads with approximately 38–39 % share of the global CGM device market in 2024. The region shipped >20 million sensor units in that year. The U.S. alone comprises ~70 % of North America’s volume. In Canada, CGM reimbursement is available in >8 provinces covering ~50 % of insulin users. In the U.S., ~4 million users are active CGM subscribers. The U.S. market also leads in adoption of OTC CGM devices, with Dexcom launching such offerings to ~25 million potential users.

North America represents approximately 35% of the global CGM market in 2025, valued at USD 535.31 million, and is projected to reach USD 923.46 million by 2034, at a CAGR of 6.29%.

North America – Major Dominant Countries in the Continuous Glucose Monitoring (CGM) Market

• United States: Market size USD 500 million (93.4%) in 2025, increasing USD 863 million by 2034 at 6.3% CAGR, supported by 5 million CGM users nationwide.
• Canada: Estimated USD 20 million (3.7%) in 2025, forecast USD 35 million by 2034 at 6.0% CAGR, driven by national diabetes coverage expansion.
• Mexico: Valued at USD 8 million (1.5%) in 2025, reaching USD 14 million by 2034 at 7.0% CAGR, amid a 10% annual rise in diabetic population.
• Costa Rica: Around USD 4 million (0.7%) in 2025, set USD 7 million by 2034 with 7.2% CAGR, due to regional med-tech imports.
• Panama: Roughly USD 3 million (0.6%) in 2025, projected USD 5 million by 2034 at 7.0% CAGR, backed by growing private-clinic usage.

EUROPE

commands ~25–30 % share of global CGM shipments. In Germany and the U.K., more than 40 % of insulin users already use CGM. In France, ~350,000 CGM users were registered in 2024. In Italy and Spain, adoption remains lower (~15–20 %), but growth exceeds 15 % annually. In Nordic nations (Denmark, Sweden, Norway), ~60–70 % of diabetics on insulin use CGM. European reimbursement schemes cover CGM in >20 countries, with full reimbursement in 12 EU member states.

Europe holds about 25% of the global CGM market, valued at USD 382.36 million in 2025 and forecast to reach USD 658.08 million by 2034 at a 6.29% CAGR.

Europe – Major Dominant Countries in the Continuous Glucose Monitoring (CGM) Market

• Germany: Market USD 80 million (20.9%) in 2025, forecast USD 138 million by 2034 at 6.2% CAGR, driven by insurance-funded CGM programs.
• United Kingdom: About USD 60 million (15.7%) in 2025, growing USD 103 million by 2034 at 6.1% CAGR, boosted by NHS device distribution.
• France: Valued USD 50 million (13.1%) in 2025, projected USD 86 million by 2034 at 6.0% CAGR, with CGM usage in 80% of hospitals.
• Italy: Around USD 45 million (11.8%) in 2025, expected USD 78 million by 2034 with 6.3% CAGR, as 1.2 million diabetics use CGM.
• Spain: Estimated USD 35 million (9.2%) in 2025, rising USD 60 million by 2034 at 6.0% CAGR, with rising CGM subsidies.

ASIA-PACIFIC

Asia-Pacific is the fastest-growing region, accounting for ~15–18 % of global shipments in 2024. In China, ~500,000 CGM units were placed in 2024; projections suggest growth to 2 million units by 2028. In India, CGM adoption rose 25 % YoY in 2023–2024; total users now exceed 150,000. Japan and South Korea represent ~40 % of APAC share; in Japan, ~200,000 CGM users were active in 2024.

Asia-Pacific accounts for nearly 30% of the global CGM market, worth USD 458.84 million in 2025, and projected USD 790.22 million by 2034 with a 6.29% CAGR.

Asia-Pacific – Major Dominant Countries in the Continuous Glucose Monitoring (CGM) Market

• China: Market USD 120 million (26.2%) in 2025, projected USD 207 million by 2034 at 7.0% CAGR, due to 140 million diabetic patients.
• Japan: Valued USD 70 million (15.3%) in 2025, reaching USD 121 million by 2034 at 6.4% CAGR, with 10% annual sensor growth.
• India: Around USD 65 million (14.2%) in 2025, projected USD 112 million by 2034 with 7.5% CAGR, driven by 75 million diabetic adults.
• South Korea: Estimated USD 40 million (8.7%) in 2025, expected USD 69 million by 2034 at 6.5% CAGR, supported by high tech-literacy.
• Australia: About USD 35 million (7.6%) in 2025, forecast USD 60 million by 2034 at 6.2% CAGR, aided by universal reimbursement coverage.

MIDDLE EAST & AFRICA

region held ~5–7 % share of global CGM shipments in 2024. In Saudi Arabia and UAE, adoption among insulin users reached ~20–25 %. In South Africa, ~30,000 CGM users were registered. Some national health schemes (e.g. UAE) cover ~50 % of sensor cost for diabetics. Market growth in MEA averaged 15 % annually over 2022–2024. In North Africa, CGM penetration remains under 2 %.

The Middle East & Africa (MEA) region holds roughly 10% of the global CGM market, valued at USD 152.95 million in 2025 and anticipated USD 263.09 million by 2034 with a 6.29% CAGR.

Middle East & Africa – Major Dominant Countries in the Continuous Glucose Monitoring (CGM) Market

• Saudi Arabia: Market USD 50 million (32.7%) in 2025, reaching USD 86 million by 2034 at 6.5% CAGR, driven by government diabetes initiatives.
• UAE: Valued USD 35 million (22.9%) in 2025, forecast USD 60 million by 2034 with 6.3% CAGR, led by smart-hospital installations.
• South Africa: About USD 25 million (16.3%) in 2025, projected USD 43 million by 2034 at 6.2% CAGR, fueled by rising diabetic prevalence (11%).
• Egypt: Around USD 20 million (13.1%) in 2025, expected USD 34 million by 2034 at 6.4% CAGR, with growing CGM imports.
• Kenya: Estimated USD 10 million (6.5%) in 2025, increasing USD 17 million by 2034 at 7.0% CAGR, driven by local tele-diabetes initiatives.

List of Top Continuous Glucose Monitoring (CGM) Companies

• Medtronic
• i-SENS Inc.
• GlucoMenDay
• Dexcom
• Abbott
• OSANG Healthcare Co. Ltd.
• TaiDoc Technology Corporation
• Sanwa Kagaku Kenkyusho Co Ltd.
• Senseonics

Dexcom — controls ~40 % of global CGM shipments; in 2025 it secured FDA clearance for a 15-day G7 sensor and an OTC version (Stelo).

Abbott — holds ~30 % share, with its FreeStyle Libre series used by >7 million people globally by 2024.

Investment Analysis and Opportunities

From an investment perspective, the Continuous Glucose Monitoring (CGM) Market presents opportunities in hardware, software/data analytics, and service layers. In 2024, CGM device shipments exceeded 50 million sensor cycles, and software subscription revenue already accounts for ~10–15 % of annual ecosystem value. Startups specializing in AI-based glycemic forecasting, with pilot user bases of >100,000, have attracted Series B funding rounds between USD 20–50 million. Public companies in the CGM sector have seen multiples expand: between 2023 and 2025, some stocks have appreciated by 20–35 % as adoption accelerates. Opportunities lie in vertical expansion: in emerging markets with diabetic populations exceeding 150 million (e.g. India, China, Brazil), the addressable CGM user base is under 5 % today. If uptake reaches 15 %, that implies >10 million additional users. Strategic investments in low-cost patch sensor manufacturing (target cost USD 20–30 per cycle) may yield unit margin expansion of 10–20 %.

Similarly, data analytics and remote coaching services can generate USD 10–25 per user per month in subscription revenue; in 2024, ~10 % of new CGM buyers selected optional data plans. Partnerships with payers and national health systems in >10 countries are underway. Investment in clinical trials to demonstrate HbA1c reductions (of 0.8–1.2 %) or reduced hypoglycemia events (by 20–30 %) strengthens payer coverage. Expansion into non-insulin type 2 population is a key tactic: OTC devices such as Dexcom’s Stelo address a potential ~25 million users in the U.S. alone. Investment in performance guarantees (outcomes-based reimbursement) is emerging, with >5 pilot programs launched globally. Moreover, cross-platform integration is an investment beachhead. In 2024, >60 % of CGM devices launched offered APIs to integrate with digital health apps, insulin pumps, and telehealth ecosystems. Investing in middleware and interoperability platforms is a clear opportunity. As sensors shrink (<1 gram) and signal processing improves, companies investing in next-gen miniaturization may reduce manufacturing costs by 15–25 % over 3–5 years.

New Product Development

Product innovation in the Continuous Glucose Monitoring (CGM) space is robust, with new devices emphasizing sensor longevity, miniaturization, connectivity, and smart analytics. In 2024, over 20 new sensor models were under development globally, including 8 implantable options. For example, Senseonics launched Eversense 365, a fully implantable sensor designed to function for 12 months between replacements. This doubles the prior generation’s lifespan of 6 months. To expand consumer access, Dexcom’s OTC product, “Stelo,” targets non-insulin users; early adoption captured ~5 % of U.S. CGM unit volume in its launch quarter. Dexcom also obtained FDA clearance for a 15-day version of the G7 sensor in 2025, extending wear time versus typical 10-day sensors. Several manufacturers are exploring 14- to 15-day patch sensors, with at least 4 new models launched in 2024. Some devices now feature modular transmitters that can survive 3–4 sensor cycles, reducing per-cycle cost by about 25 %. Miniaturization efforts are pushing sensors below 1 mm thickness and weights <0.8 g. In 2024, ~30 % of developmental sensors achieved that threshold. The new sensors may require fewer calibrations: several prototypes require only 1 fingerstick/day or even no fingerstick calibrations for the first 24 hours.

Another frontier is biocompatible coatings to reduce inflammation and extend functional life: >50 % of new prototypes incorporate hydrophilic membranes, reducing signal drift by 20–30 %. Wireless power and energy harvesting are being integrated: 3–4 developers reported sensors powered by ambient radio frequency (RF) energy, eliminating internal batteries. Several sensor makers are embedding edge-AI processing, allowing on-sensor slope filtering and anomaly detection. >10 products in pilot trials in 2025 analyze glycemic variability metrics directly on-device, delivering alerts for >90 % of predictive hypoglycemia events. Connectivity is being upgraded: >65 % of new CGMs support Bluetooth 5.4 or low-energy WiFi scanning. Integration with insulin pumps or closed-loop systems is tight: ~12 new algorithms are under clinical validation. Some new products allow multi-analyte sensing: glucose + lactate + ketone in a single sensor, currently in prototype stage. In summary, new product development in the Continuous Glucose Monitoring (CGM) market emphasizes longer lifespan, lower calibration burden, miniaturized form factor, smarter analytics, multi-analyte capability, and fully wireless architecture.

Five Recent Developments

• Senseonics Eversense 365 clearance: In 2024, Senseonics achieved FDA clearance for its implantable CGM sensor operating for 12 months between replacements.
• Dexcom OTC CGM launch: In 2024, Dexcom obtained regulatory approval for its over-the-counter CGM product “Stelo,” targeting ~25 million type 2 diabetics without insulin therapy.
• Dexcom 15-day G7 approval: In 2025, Dexcom secured regulatory clearance for a 15-day sensor version of its G7, extending wear time beyond earlier 10-day designs.
• Adoption surge in India: During 2023–2024, CGM adoption in India increased by ~25 % year on year, reaching >150,000 users.
• European reimbursement expansion: Between 2023 and 2025, 5 additional EU countries implemented national CGM reimbursement programs, covering >30 % of diabetic populations in those markets.

Report Coverage of Continuous Glucose Monitoring (CGM) Market

This Continuous Glucose Monitoring (CGM) Market Report provides comprehensive coverage across multiple dimensions of the global CGM industry. It includes historical data from 2018 onward, current year metrics (2024/2025), and forecasts through 2030. The Report covers unit shipments (sensor cycles, transmitters, integrated pump systems), installed user base by region, and adoption rates by diabetes type and insulin use. The Market Research Report details market share by component (sensors, transmitters/receivers, pump-integrated systems) and by application (hospital/institutional vs homecare). The Continuous Glucose Monitoring (CGM) Industry Report includes regional breakdowns—North America, Europe, Asia-Pacific, Middle East & Africa—and country-level detail for >20 markets, with market penetration rates, reimbursement coverage percentages, and annual growth trends. The Continuous Glucose Monitoring (CGM) Market Forecast module provides projections of device volumes, installed base, and technology diffusion by sensor type (short-term patches, extended wear, implantables). 

The report addresses key drivers, restraints, challenges, and opportunities in the market. It discusses regulatory frameworks, reimbursement landscape, clinical validation benchmarks (e.g., mean absolute relative difference, drift profiles), and interoperability standards. The coverage includes new product development, detailing >30 devices in development, innovation trends (miniaturization, multi-analyte sensing, wireless power), and software/analytics ecosystems. The Market Insights module presents user behavior data: adoption rates by patient demographic, retention/discontinuation percentages (e.g., 20 % drop-out in first year), and real-world outcomes (HbA1c reduction ranges, hypoglycemia event reductions). Additionally, the report includes an Investment Outlook and Opportunities section covering capital flows, funding rounds, merger & acquisitions, and licensing deals. It highlights >15 startup investments and >10 cross-licensing deals in the CGM space. 

Continuous Glucose Monitoring (CGM) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1625.6 Million in 2026
Market Size Value By	USD 2813.82 Million by 2035
Growth Rate	CAGR of 6.29% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Transmitters & Receivers Sensors Insulin Pumps By Application : Hospital Homecare
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample